After checking the capability of KRAS antibody for immunoprecipitation (Supplementary Fig. 3c), we examined the cellular interaction of endogenous KRAS and DX2 in colorectal adenocarcinoma DLD-1 cells and observed that the binding of the two proteins was enhanced by EGF treatment (Fig. 2e). Here, KRAS is linked to colorectal adenocarcinoma.